Drug Margins Could Be Dampened By Medicare Drug Benefit - IMS
Executive Summary
The prosperity of the prescription drug market could be challenged by passage of a Medicare drug benefit, IMS Health VP-Supplier Relations Douglas Long said at the Pharmaceutical Care Management Association annual meeting in Tucson, Ariz. Oct. 17.
You may also be interested in...
Chain Rx Volume To Grow At Double Rate Of Mail-Order In '99 - NACDS
The number of prescriptions filled by traditional chain drug stores in 1999 is expected to increase 11% over 1998, more than twice the rate of growth for mail-order scripts, according to projections released at the National Association of Chain Drug Stores Pharmacy & Managed Care Forum in San Diego Aug. 30.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials